ESMO 2017 | Overcoming resistance to immunotherapy
Grant McArthur, MBBS, BMedSc, PhD, FRACP, from the The Peter MacCallum Cancer Centre, Melbourne, Australia, talks about how we are trying to answer one of the biggest questions in oncology. How can we overcome resistance to immunotherapy? He disucusses resistance to systemic therapies in general, including targeted therapies. He explains that, despite promising results, many patients are primary refractory to PD1-based therapies. Studies in melanoma are exploring these issues and there are specific hard-to-treat patient groups where this is being investigated. Video recorded at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up